NCT06669806招募中不适用
A Prospective, Multi-Center, Single-Arm Clinical Study to Evaluate the Effectiveness and Safety of LIVERTYTM TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension
C. R. Bard1 个研究点 分布在 1 个国家目标入组 166 人开始时间: 2024年11月21日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 166
- 试验地点
- 1
- 主要终点
- Stent patency rate after treatment completion*
研究概览
简要总结
This Study is a prospective, multi-center, single-arm objective perform an criteria (OPC) study. A 12 months follow-up study on the patients who intend to receive the treatment of cirrhosis and complications of portal hypertension with the TIPS Stent Graft will be conducted. The primary evaluation endpoint of this Study is the stent patency at 6 months after treatment completion .
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject who is 18 years old or above but 75 years old or below;
- •The subject who is diagnosed with portal hypertension caused by liver cirrhosis with the history of gastrointestinal variceal bleeding or bleeding, hepatic hydrothorax, and refractory or recurrent ascites;
- •The subject must have adequate functional hepatic reserve with a Model for End-Stage Liver Disease (MELD) Score of ≤13 or Child-Pugh Score of ≤18;
- •The subject with platelet count≥ 20×10^9 /L;
- •Subjects or their guardians who can understand the content of the clinical trial, voluntarily participate in the clinical trial and sign the ICF and can complete the follow-up period according to the requirements of the clinical trial.
排除标准
- •The subject who is pregnant or lactating or plan to get pregnant during the clinical trial;
- •According to the judgment of investigator, the subject with main portal vein thrombosis which thrombus occupying >50% of the portal vein lumen and affecting postoperative hemodynamics;
- •The subject who has received surgical or interventional treatment (such as TIPS, surgical shunt and retrograde transvenous obliteration (-RTO) for treatment of complications from portal hypertension. Note: The subject who have received -RTO for variceal bleeding at least 8 weeks before signing the informed consent form can be included in the clinical trial;
- •The subject who needs to receive or have received splenectomy;
- •The subject who has received or plan to receive liver transplantation;
- •The subject who cannot have a shunt channel established in the liver parenchyma between the hepatic vein and the portal vein as determined by the investigators;
- •The subject with extrahepatic or hepatic malignancies;
- •The subject with Budd-Chiari syndrome and hepatic sinusoidal obstruction syndrome;
- •The subject with congenital cystic dilatation of bile duct (Caroli disease) and obstructive dilation of biliary tract;
- •The subject with polycystic liver disease;
- •The subject with cavernous transformation of the portal vein;
- •The subject with severe or refractory hepatic encephalopathy (Grade 2 or above according to the West Haven Criteria);
- •The subject with a TBIL level higher than 51.3 μmol/L (excluding the Patients with cholestatic cirrhosis);
- •The subject with coagulation disorders (INR: >2.5);
- •The subject with a systolic pressure lower than 80 mmHg;
- •The subject with severe tricuspid regurgitation or congestive heart failure;
- •The subject with myocardial infarction within the past 3 months;
- •The subject with moderate to severe pulmonary arterial hypertension, or severe hepatopulmonary syndrome;
- •The subject with uncontrolled systemic infection or inflammation;
- •The subject with severe renal insufficiency (Scr level:>199.5 μmol/L) or needing to receive dialysis;
- •The subject known to be allergic to the contrast media or to the constituent materials of the TIPS covered segment;
- •The subject with the history of epilepsy or mental illness or with cognitive impairment;
- •The subject with the expected survival time of less than 1 year;
- •The subject who is otherwise determined as ineligible for participation in this Study by investigators;
- •The subject who is participating in any other unfinished drug or medical device clinical trials.
结局指标
主要结局
Stent patency rate after treatment completion*
时间窗: 6 months
次要结局
- Technical success rate(immediately after the intervention)
- The proportion of clinical improvement on hepatic hydrothorax after treatment completion*(3 months, 6 months, and 12 months)
- TEP related adverse events (AE) after treatment completion*(6 months and 12 months)
- Serious adverse events (SAE) after index procedure(6 months and 12 months)
- Hemodynamic success rate(immediately after the intervention)
- Stent patency rate after treatment completion*(1 month, 3 months and 12 months)
- Incidence of subjects free from receiving TIPS shunt reoperation after treatment completion*(1 month, 3 months, 6 months and 12 months)
- Incidence of subjects free from severe hepatic encephalopathy after treatment completion*(1 month, 3 months, 6 months and 12 months)
- Incidence of subjects free from rebleeding after treatment completion*(1 month, 3 months, 6 months and 12 months)
- Liver transplant-free survival rate post-index procedure(6 months and 12 months)
- The proportion of clinical improvement on ascites after treatment completion*(3 months, 6 months, and 12 months)
- Overall survival rate post-index procedure(1 month, 3 months, 6 months and 12 months)
- Incidence of medical device-related and/or operation-related severe complications(1 month)
- Adverse events (AE) after index procedure(6 months and 12 months)
- Device deficiencies(through study completion, an average of 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
The Multicenter Clinical Trial of a Novel TEER Decive (V-CLASP Trial)Mitral RegurgitationNCT05391802Shanghai Zhongshan Hospital120
终止
不适用
Safety and Efficacy of Intracranial Thrombus Aspiration Catheter in the Treatment of Acute Large-vessel Occlusive StrokeAspirationAcute Ischemic StrokeLarge-vessel OcclusionNCT05101668Sinomed Neurovita Technology Inc.26
终止
不适用
Prospective Clinical Study of the Guidant Microwave Ablation System for the Treatment of PAF in the MIS ProcedureAtrial FibrillationNCT00415558Maquet Cardiovascular
招募中
2 期
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsNon-clear Renal Cell CarcinomaNCT05768464The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School30
终止
不适用
The Pristine Post-Market StudyHemodialysis ComplicationHemodialysis Catheter InfectionHemodialysis Access FailureCentral Venous Catheter Related Bloodstream InfectionEnd Stage Renal DiseaseKidney Failure, ChronicNCT05228132C. R. Bard142